Investment Thesis
Rapport Therapeutics is an early-stage biopharmaceutical company with severely deteriorating fundamentals: $20M revenue generating -$24.2M operating losses and -$13.1M negative operating cash flow. While the balance sheet is solid with $471.5M equity and $78.1M cash providing ~6 years of runway at current burn rates, the company lacks meaningful revenue traction and profitability pathway, making it a speculative R&D-stage investment with significant execution risk and no proven commercial viability.
Strengths
- Strong balance sheet with $471.5M stockholders equity and minimal leverage (0.00x debt-to-equity)
- Adequate cash reserves of $78.1M provides operational runway at current burn rate
- Exceptional liquidity position with 27.08x current ratio demonstrates short-term financial stability
- Modest improvement in per-share losses (EPS improved 24.3% YoY) suggests potential operational efficiency gains
Risks
- Severe operating losses of -$24.2M against only $20M revenue indicate massive cash burn relative to revenue generation
- Negative operating cash flow of -$13.1M and -65.7% FCF margin shows inability to self-fund operations
- Early-stage biotech with unproven pipeline, no visibility into clinical success or regulatory approval timelines
- Significant runway depletion risk if development programs fail or burn rate accelerates beyond current -$13.1M annual pace
Key Metrics to Watch
- Quarterly operating cash flow and cash burn rate trajectory
- Clinical trial milestone achievements and regulatory filing progress
- Revenue growth and commercial revenue ramp from approved or near-approval products
- Cash runway sufficiency relative to major near-term development milestones
Financial Metrics
Revenue
20.0M
Net Income
-19.9M
EPS (Diluted)
$-0.42
Free Cash Flow
-13.1M
Total Assets
497.6M
Cash
78.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-121.1%
Net Margin
-99.3%
ROE
-4.2%
ROA
-4.0%
FCF Margin
-65.7%
Balance Sheet & Liquidity
Current Ratio
27.08x
Quick Ratio
27.08x
Debt/Equity
0.00x
Debt/Assets
5.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:04:13.313763 |
Data as of: 2026-03-31 |
Powered by Claude AI